An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma.
暂无分享,去创建一个
F. Feuerhake | M. McGurk | J. Soria | F. Farzaneh | S. Evers | P. Delmar | S. Temam | L. Manenti | A. Hollebecque | J. Delord | C. Mancao | J. Spicer | L. Andries | K. Hussain | J. Sarini | A. Passioukov | M. Ott | D. Oppenheim | L. Di Scala | S. Soehrman Brossard